comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 23:33:37 - browse：2945

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Boston Scientific acquires urology company Axonics for $3.7 billion

focus

WSS

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Merck to acquire Harpoon Therapeutics for $680 million

Stories you might have missed in 2023: health, science, medicine

The debate over Covid

American taxpayers paid $1.8 trillion in health care costs in 2022

hotspot

comprehensive

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Dobbs anniversary: the lost opportunity of abortion as health care

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Activists slam private health insurers over coverage restrictions

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Drug repurposing or repositioning? The language matters

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

Stories you might have missed in 2023: health, science, medicine

Boston Scientific acquires urology company Axonics for $3.7 billion

Digital health funding stays low as a new reality sets in

Merck to acquire Harpoon Therapeutics for $680 million

Nonprofit, backed by Microsoft, to certify AI tools in health care

Cuban government calls US nuclear submarine stop a 'provocative escalation'

hotspot

explore

focus

hotspot